Otros idiomas Aethlon Medical, Inc.

Acciones

AEMD

US00808Y4061

Diferido Nasdaq Otros sitios de cotización 17:29:59 26/06/2024			Varia. Cinco días.	Varia. 1 de enero.
0,5898 ^USD	-5,59 %		-0,03 %	-73,07 %

18/06	Aethlon Medical, Inc. Recibe la Aprobación del Comité Ético para el Ensayo de Hemopurifier® contra el Cáncer	CI
03/06	Aethlon Medical, Inc. se prepara para estudios de fase 1 potencialmente transformadores para el tratamiento del cáncer	CI

Otros idiomas

Desbloquee todas las noticias sobre todas las empresas: ¡No vuelvas a perderse una oportunidad de inversión rentable!

Inscripción 100% Gratuita

Aethlon Medical to Release Fiscal Year End Financial Results and Host Conference Call on June 27, 2024	21/06
What's Next in Treatments for Cancer Patients with Solid Tumors?	20/06
Aethlon Medical Receives Ethics Committee Approval for Hemopurifier Cancer Trial	19/06
Top Small-Cap Stocks Leading the Market Surge: ASNS, PRSO, RELI, VTAK, AEMD	19/06
Aethlon Medical Receives Ethics Committee Approval for Hemopurifier® Cancer Trial	18/06
Aethlon Medical, Inc. Receives Ethics Committee Approval for Hemopurifier® Cancer Trial	18/06
Exploring Top NASDAQ Stocks Under $1 Gaining Traction: KITT, AEMD, VTAK, TELL, KWE	12/06
The Hunt for Virus Treatments Continues Post Covid-19	07/06
Blood Purification Medical Devices Revolutionizing the Future of Health from Cancer to COVID	03/06
Aethlon Medical Prepares for Potentially Transformative Phase 1 Cancer Treatment Studies	03/06
Aethlon Medical, Inc. Prepares for Potentially Transformative Phase 1 Cancer Treatment Studies	03/06
Top Midday Decliners	15/05
Aethlon Medical Announces Pricing of $4.7 Million Public Offering	15/05
Aethlon Medical Reports Positive Results from an In Vitro Binding Study of Its Hemopurifier in Removing Extracellular Vesicles from Cancer Patient Plasma	13/05
Wall Street Set to Open Higher Monday as Investors Look Toward Key Inflation Figures	13/05
Investors Eye Key Inflation Data in Days Ahead as US Futures Trend Modestly Higher Monday	13/05
Aethlon Medical Reports Positive Results From an In Vitro Binding Study of Its Hemopurifier® in Removing Extracellular Vesicles From Cancer Patient Plasma	10/05
Aethlon Medical, Inc. Reports Positive Results from an In Vitro Binding Study of Its Hemopurifier in Removing Extracellular Vesicles from Cancer Patient Plasma	10/05
Aethlon Medical : Corporate Overview – May 2024	10/05
Aethlon Medical : Corporate Presentation April 2024	25/04

No hay resultados para esta búsqueda

Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Otros idiomas Aethlon Medical, Inc.

Acciones

AEMD

US00808Y4061

Otros idiomas

Filtros